BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
NCT ID: NCT01603615
Last Updated: 2019-08-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
220 participants
INTERVENTIONAL
2012-10-30
2018-09-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity
NCT01603641
BOTOX® Treatment in Pediatric Upper Limb Spasticity
NCT01603602
BOTOX® Treatment in Pediatric Lower Limb Spasticity
NCT01603628
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
NCT01387074
Botulinum Toxin (BOTOX) for Cerebral Palsy
NCT00060957
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BOTOX®
Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study.
Botulinum Toxin Type A
Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botulinum Toxin Type A
Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Upper limb spasticity due to cerebral palsy or stroke
Exclusion Criteria
* Uncontrolled epilepsy
* Botulinum Toxin therapy of any serotype for any condition within the last 3 months
* History of surgical intervention of the upper limb within 1 year, or planned surgery of any limb during the study
2 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emily McCusker
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ABS Health, LLC
Pasadena, California, United States
Harrison Clinical Management
Pomona, California, United States
Rady Children's Hospital San Diego
San Diego, California, United States
Children's Hospital Colorado Dept. of PM&R
Aurora, Colorado, United States
Associated Neurologists of Southern Connecticut, P.C.
Fairfield, Connecticut, United States
New England Center for Clinical Research
Stamford, Connecticut, United States
NW FL Clinical Research Group, LLC
Gulf Breeze, Florida, United States
Axcess Medical Research, LLC
Loxahatchee Groves, Florida, United States
Pediatric Neurology, PA
Orlando, Florida, United States
Children's Healthcare of Atlanta Children's Rehabilitation Associates
Atlanta, Georgia, United States
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota, United States
The Children's Mercy Hospital & Clinics
Kansas City, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Clinical Research Center of New Jersey
Voorhees Township, New Jersey, United States
NYU Hospital for Joint Diseases
New York, New York, United States
Columbia University Pediatric Physical Medicine & Rehabilitation, Dept. of Rehabilitation & Regenerative Medicine Harkness
New York, New York, United States
OnSite Clinical Solutions, LLC
Charlotte, North Carolina, United States
PMG Research of Charlotte, LLC
Charlotte, North Carolina, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Baylor College of Medicine Texas Children's Hospital
Houston, Texas, United States
Road Runner Research
San Antonio, Texas, United States
Seattle Children's Hospital
Seattle, Washington, United States
Marshfield Clinic
Marshfield, Wisconsin, United States
Holland Bloorview Kids Rehab
Toronto, Ontario, Canada
Debrecen University Clinical Center, Orthopedic Clinic
Debrecen, , Hungary
De La Salle Health Sciences Institute
Cavite, , Philippines
Philippine Children's Medical Center
Quezon City, , Philippines
Uni Centrum Kliniczne
Gdansk, , Poland
Specjal. Gabinet Neurologiczny
Krakow, , Poland
Centrum Medyczne "POMOC"
Lodz, , Poland
INTERMED, Lublin
Lublin, , Poland
CRH ŻAGIEL MED, Lublin
Lublin, , Poland
Centrum Profilatyki I Terapii
Warsaw, , Poland
NZOZ Mazowieckie Centrum
Warsaw, , Poland
Childrens Republic Hospital
Kazan', , Russia
Smolensk Regional Hospital- Regional Budget State Healthcare institution
Smolensk, , Russia
Tyumen Regional Hospital #2 - State Budget Healthcare Institution of Tyumen region
Tyumen, , Russia
Daegu Fatima Hospital
Daegu, , South Korea
National Health Insurance Service Ilsan Hospital
Gyeonggi-do, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Siriraj Hospital Dept of Rehabilitation Medicine, Faculty of Medicine
Bangkok, , Thailand
Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University
Chiang Mai, , Thailand
Srinagarind Hospital, Khon Kaen University
Khon Kaen, , Thailand
Kocaeli Üniversitesi
Kocaeli, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
More information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-000043-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
191622-105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.